

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
20 January 2005 (20.01.2005)

PCT

(10) International Publication Number  
**WO 2005/004870 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/517**,  
31/282, A61P 35/00

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,  
S-151 85 Sodertälje (SE).

(21) International Application Number:  
PCT/GB2004/002932

(22) International Filing Date: 7 July 2004 (07.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0316176.7 10 July 2003 (10.07.2003) GB  
0406546.2 24 March 2004 (24.03.2004) GB  
0407753.3 6 April 2004 (06.04.2004) GB

(71) Applicant (for all designated States except MG, US): **AS-  
TRAZENECA AB** [SE/SE]; Sodertälje, S-151 85 (SE).

(71) Applicant (for MG, only): **ASTRAZENECA UK LIM-  
ITED** [GB/GB]; 15 Stanhope Gate, London Greater Lon-  
don W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WEDGE, Stephen**,  
Robert [GB/GB]; AstraZeneca R & D Alderley, Alderley  
Park, Macclesfield Cheshire SK10 4TG (GB). **RYAN, An-  
derson, Joseph** [GB/GB]; AstraZeneca R & D Alderley,  
Alderley Park, Macclesfield Cheshire SK10 4TG (GB).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AI, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: **USE OF THE QUINAZOLINE DERIVATIVE ZD6474 COMBINED WITH PLATINUM COMPOUNDS AND OP-  
TIONALLY IONISING RADIATION IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS AND/OR  
INCREASED VASCULAR PERMEABILITY**

(57) Abstract: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability re-  
ducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a  
method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of ZD6474  
in combination with a platinum anti-tumour agent; to a pharmaceutical composition comprising ZD6474 and a platinum anti-tumour  
agent; to a combination product comprising ZD6474 and a platinum anti-tumour agent for use in a method of treatment of a human  
or animal body by therapy; to a kit comprising ZD6474 and a platinum anti-tumour agent; to the use of ZD6474 and a platinum  
anti-tumour agent in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability  
reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.

WO 2005/004870 A1